NZ243435A - Monoclonal antibody specific for a tumour antigen, its use and the cell line responsible for its production - Google Patents

Monoclonal antibody specific for a tumour antigen, its use and the cell line responsible for its production

Info

Publication number
NZ243435A
NZ243435A NZ243435A NZ24343592A NZ243435A NZ 243435 A NZ243435 A NZ 243435A NZ 243435 A NZ243435 A NZ 243435A NZ 24343592 A NZ24343592 A NZ 24343592A NZ 243435 A NZ243435 A NZ 243435A
Authority
NZ
New Zealand
Prior art keywords
antibody
monoclonal antibody
cell line
cells
antigen
Prior art date
Application number
NZ243435A
Other languages
English (en)
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NZ243435A publication Critical patent/NZ243435A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ243435A 1991-07-03 1992-07-03 Monoclonal antibody specific for a tumour antigen, its use and the cell line responsible for its production NZ243435A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
NZ243435A true NZ243435A (en) 1994-10-26

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ243435A NZ243435A (en) 1991-07-03 1992-07-03 Monoclonal antibody specific for a tumour antigen, its use and the cell line responsible for its production

Country Status (19)

Country Link
US (1) US5552293A (enExample)
EP (1) EP0521842B1 (enExample)
JP (1) JP3194020B2 (enExample)
KR (1) KR100246681B1 (enExample)
AT (1) ATE171193T1 (enExample)
AU (2) AU658198B2 (enExample)
CA (1) CA2073124C (enExample)
DE (1) DE69226990T2 (enExample)
DK (1) DK0521842T3 (enExample)
EE (1) EE03031B1 (enExample)
ES (1) ES2124250T3 (enExample)
FI (1) FI109207B (enExample)
HU (2) HU218084B (enExample)
IE (1) IE80841B1 (enExample)
IL (1) IL102390A (enExample)
NO (1) NO315472B1 (enExample)
NZ (1) NZ243435A (enExample)
SE (1) SE9102074D0 (enExample)
WO (2) WO1993001302A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
JP2004537976A (ja) * 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1651162B1 (en) 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
DK2594591T3 (en) * 2005-08-11 2018-07-30 Matossian Rogers Arpi TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
MX337991B (es) 2008-08-05 2016-03-30 Toray Industries Metodo para detectar cancer.
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EP2904089A4 (en) 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
EP3411409B1 (en) 2016-01-10 2025-10-08 Neotx Therapeutics Ltd. Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
WO2019035034A1 (en) * 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
EP4732850A1 (en) 2024-10-25 2026-04-29 Antelope Therapeutics SAS Antibody-drug conjugates and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
AU656906B2 (en) * 1990-07-20 1995-02-23 Active Biotech Ab Target specific antibody-superantigen conjugates and their preparation

Also Published As

Publication number Publication date
DE69226990T2 (de) 1999-03-25
KR100246681B1 (ko) 2000-04-01
CA2073124A1 (en) 1993-01-04
SE9102074D0 (sv) 1991-07-03
NO934777L (no) 1994-02-11
WO1993001303A1 (en) 1993-01-21
ATE171193T1 (de) 1998-10-15
IL102390A (en) 1996-01-19
EP0521842A3 (enExample) 1994-01-26
IL102390A0 (en) 1993-01-14
EP0521842B1 (en) 1998-09-16
CA2073124C (en) 2007-06-19
NO934777D0 (no) 1993-12-22
EP0521842A2 (en) 1993-01-07
NO315472B1 (no) 2003-09-08
JP3194020B2 (ja) 2001-07-30
HU9400011D0 (en) 1994-05-30
FI109207B (fi) 2002-06-14
ES2124250T3 (es) 1999-02-01
HU211512A9 (en) 1995-11-28
EE03031B1 (et) 1997-08-15
HUT71193A (en) 1995-11-28
HU218084B (hu) 2000-05-28
AU658198B2 (en) 1995-04-06
FI935970A0 (fi) 1993-12-31
DK0521842T3 (da) 1999-06-14
DE69226990D1 (de) 1998-10-22
US5552293A (en) 1996-09-03
JPH05276987A (ja) 1993-10-26
IE80841B1 (en) 1999-03-24
IE922188A1 (en) 1993-01-13
WO1993001302A1 (en) 1993-01-21
AU1942592A (en) 1993-01-07
FI935970L (fi) 1993-12-31
AU2292092A (en) 1993-02-11

Similar Documents

Publication Publication Date Title
US5552293A (en) Tumor antigen specific antibody
JP4124486B2 (ja) ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
JP3053873B2 (ja) Ｂ細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
JP3492373B2 (ja) モノクローナル抗体
CA2200868C (en) Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies
RU2266298C2 (ru) Антитела к антигену эпителиальных опухолей желудочно-кишечного тракта человека, родственному альфа 6 бета 4 интегрину
JP2000511421A5 (enExample)
JP7063623B2 (ja) 治療用抗体およびその使用
JP2001501801A (ja) モノクローナル抗体ｂｒ１１０およびその使用
JP2935520B2 (ja) ガン治療に用いられる新規高親和性改変抗体系統群
CA2132540C (en) A monoclonal antibody to a human mdr1 multidrug resistance gene product, and uses
WO2000032635A2 (en) Tumor specific human monoclonal antibodies and methods of use
EP3619237B1 (en) Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
CA2255540C (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
CA3062233C (en) Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
AU7243200A (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
NZ505305A (en) Antigen binding fragments that inhibit an antibody comprising amino acid sequences of H and L chain V regions of a scFv from binding to the surface of a cancer cell
WO2001040292A1 (en) Antigen-binding fragments specific for tumor associated antigens

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired